Krasean Panyakhamlerd

A randomized trial of oral contraceptive and hormone replacement therapy on bone mineral density and coronary heart disease risk factors in postmenopausal women

Objective To identify the effects of oral contraceptive (OC) and hormone replacement therapy (HRT) on bone mineral density and coronary heart disease risk factors in postmenopausal women. Methods Eighty healthy postmenopausal women were randomly assigned to a cyclic regimen of OC containing 30 μg of ethinyl estradiol and 150 μg of desogestrel or HRT containing 0.625 mg of conjugated equine estrogens 21 days per cycle and 5 mg of medrogestone 10 days per cycle for 12 months. Bone mineral density of lumbar spine and hip, biochemical markers of bone turnover, lipid-lipoprotein profiles, coagulation profiles, fasting plasma glucose, and blood pressure were evaluated. Results Both regimens caused significant increase in bone mineral density of lumbar spine, trochanter, intertrochanteric region, total hip, and Ward triangle. Only OC therapy was associated with a significant increase in femoral neck bone mineral density (mean score ± standard error 2.5% ± 0.7%, P < .01). Biochemical markers of bone turnover, total cholesterol, and low-density lipoprotein cholesterol decreased significantly in both groups. Posttreatment levels of those bone markers and lipid-lipoprotein were significantly lower after OC therapy than HRT. Fasting plasma glucose and systolic blood pressure decreased significantly in both groups; however, only the OC group showed a significant decrease in diastolic blood pressure. Conclusion Both OC and HRT increased bone mineral density of lumbar spine and hip, but OC suppressed bone turnover more than HRT. Both methods favorably affected lipid-lipoprotein metabolism, fasting plasma glucose, and blood pressure during the 12 months of treatment.

Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy?

Abstract Objectives The primary objective of this study was to evaluate the correlation among symptoms, signs, and the number of lactobacilli in postmenopausal vaginal atrophy. The secondary objective was to develop a new parameter to improve the correlation. Study design A cross-sectional descriptive study. Methods Naturally postmenopausal women aged 45–70 years with at least one clinical symptom of vaginal atrophy of moderate to severe intensity were included in this study. All of the objective parameters (vaginal atrophy score, vaginal pH, the number of lactobacilli, vaginal maturation index, and vaginal maturation value) were evaluated and correlated with vaginal atrophy symptoms. A new parameter of vaginal atrophy, vaginal atrophy symptoms II, was developed and consists of the two most bothersome symptoms (vaginal dryness and dyspareunia). Vaginal atrophy symptoms II was analyzed for correlation with the objective parameters. Results A total of 132 naturally postmenopausal women were recruited for analysis. Vaginal pH was the only objective parameter found to have a weak correlation with vaginal atrophy symptoms (r = 0.273, p = 0.002). The newly developed vaginal atrophy symptoms II parameter showed moderate correlation with vaginal pH (r = 0.356, p < 0.001) and a weak correlation with the vaginal atrophy score (r = 0.230, p < 0.001). History of sexual intercourse within 3 months was associated with a better correlation between vaginal atrophy symptoms and the objective parameters. Conclusion Vaginal pH was significantly correlated with vaginal atrophy symptoms. The newly developed vaginal atrophy symptoms II was associated with a better correlation. The vaginal atrophy symptoms II and vaginal pH may be better tools for clinical evaluation and future study of the vaginal ecosystem.

Effectiveness of a low dose testosterone undecanoate to improve sexual function in postmenopausal women

BackgroundAdding testosterone to hormonal therapy could improve sexual function and general well-being among women during climacteric. We evaluated the effectiveness of testosterone undecanoate on sexual function in postmenopausal women utilizing the standardized questionnaire FSFI score.MethodsPostmenopausal women with sexual complaints and Female Sexual Function Index (FSFI) ≤ 26.5 were enrolled in to this randomized, double-blinded, placebo-controlled trial. Participants were randomly assigned to 8-week treatment with either oral testosterone undecanoate 40 mg or placebo twice weekly with daily oral estrogen. The FSFI scores before and after treatment were compared to assess any improvement of sexual function.ResultsSeventy women were recruited of which each group had 35 participants. The baseline characteristics and baseline FSFI scores were comparable between both groups. After 8 weeks of treatment, the FSFI scores significantly improved in both groups when compared to the baseline but the FSFI scores from the testosterone group were significantly higher than in the placebo group post-treatment (28.6 ± 3.6, 25.3 ± 6.7, respectively, p = 0.04). There was no difference in adverse effect between the two groupsConclusionsThe twice weekly addition of testosterone undecanoate to daily oral estrogen was associated with a significant improvement in sexual function among postmenopausal women than the use of the estrogen alone.Trial registrationClinicalTrials.gov Identifier NCT01724658 (February 17, 2012).

Value of Osteoporosis Self-assessment Tools for Asians (OSTA) with or without Brown's clinical risk factors in detection of postmenopausal osteoporosis

ABSTRACT Objective To evaluate the value of Osteoporosis Self-assessment Tools for Asians (OSTA) score, Browns clinical risk assessment and their combination as screening tools for postmenopausal osteoporosis. Methods Two hundred postmenopausal women were enrolled between August 2010 and January 2011. The weight and age of all participants were collected for the OSTA score. Clinical risk factors were collected for Browns criteria. Bone mineral density was measured using dual-energy X-ray absorptiometry. Results The mean age (± standard deviation (range)) of the studied population was 60.1 ± 7.8 (41–81) years. Twenty-one percent of the participants had either osteoporosis of the lumbar spine, or femoral neck or both, of which 8% had osteoporosis at the lumbar spine and 17% had osteoporosis at the femoral neck. The sensitivity and specificity for OSTA score cut-off values of ≤ −1 were 78.6% and 58.2% and for Browns clinical risk factors were 57.1% and 71.5%, respectively. When the OSTA score of ≤ −1 and Browns clinical risk factors were combined to screen participants with positive values for one or both test(s), the sensitivity increased from 78.6% to 81.0%, while the specificity decreased from 58.2% to 50.6%. The positive predictive values of the OSTA score, Browns clinical criteria and the combined tools ranged between 30.4 and 70.6%. Conclusions An OSTA score of ≤ −1 seems to have higher sensitivity compared to Browns clinical risk factor assessment. The combination of both tools provides a slight improvement in sensitivity but with a decline in specificity.

Correlation of plasma microRNA-21 expression and bone turnover markers in postmenopausal women

Abstract Objectives: This study assessed the correlation of plasma microRNA-21 expression and bone turnover markers (BTMs: CTx, P1NP) in healthy Thai postmenopausal women. We secondarily compared microRNA-21 expression between participants with normal and low bone mineral density (BMD: osteopenia and osteoporosis). Methods: Postmenopausal women who had never been diagnosed with fracture or never used anti-osteoporosis drugs were included in this study. Baseline characteristics were collected from all 195 participants. BTMs and plasma miR-21-5p were analyzed from blood collection at 8:00 and 9:00 am after overnight fasting for at least 8 h. Results: There was no significant correlation between miR-21-5p and any of the BTMs (CTx, r = 0.094, p = 0.19; P1NP, r = 0.05, p = 0.485). Significant correlation between miR-21-5p and P1NP was found when participants were further categorized into those aged ≥70 years (r = 0.46, p = 0.05) and those having osteoporosis (r = 0.51, p = 0.06). Slight negative correlations were found between miR-21-5p and BMD. There was statistically significant higher expression of miR-21-5p in those with low BMD when compared to the normal BMD group (p < 0.01). Conclusion: In this study, we did not find significant correlation between plasma microRNA-21-5p expression and the BTMs. Nevertheless, there seemed to be higher expression of miR-21-5p in the low BMD participants.

The effect of vitamin D2 supplementation on muscle strength in early postmenopausal women: a randomized, double-blind, placebo-controlled trial

Abstract Background: Low serum 25-hydroxyvitamin D [25(OH)D] has been shown to be associated with low muscle mass and loss of muscle strength, resulting in increased disability and frailty in older men and women. Vitamin D deficiency is common in postmenopausal women. The primary objective of the present study was to evaluate the effects of vitamin D supplementation on muscle strength in early postmenopausal women. The effects of vitamin D2 supplementation on muscle mass and muscle cross-sectional area (CSA) were secondarily investigated. Methods: A 12-week, prospective, randomized, double-blind, placebo-controlled trial was conducted in early postmenopausal women (45–60 years old) with vitamin D deficiency (serum 25(OH)D < 20 ng/ml). A total of 88 subjects were randomized into group I: vitamin D2 supplement 40 000 IU/week (n = 44), or group II: placebo (n = 44). Serum 25(OH)D level, muscle strength, muscle mass and muscle CSA were assessed at baseline and 12 weeks after the supplementation. Results: After 12 weeks of supplementation, 70% of women in group I achieved a sufficient level of serum 25(OH)D (>30 ng/ml). There were significant differences in changes of serum 25(OH)D levels between the two groups (p < 0.05). Muscle strength and muscle CSA in group I increased significantly after 12 weeks (p = 0.015, 0.045, respectively). However, there were no significant differences in the mean changes of muscle strength, muscle mass and muscle CSA between the two groups (p = 0.16, 0.89, 0.84, respectively). Conclusion: In this study, we found no obvious effect of vitamin D supplementation on the changes in muscle strength, muscle mass and muscle CSA when compared to placebo. However, there were significant changes in muscle strength and muscle CSA from baseline in the vitamin D supplementation group.

Effect of multivitamin on serum 25-hydroxy vitamin D level in postmenopausal women: A randomized, double-blind, placebo-controlled trial

Objectives To determine the effects of multivitamin vitamin D 300 or 600 units on serum 25 hydroxyvitamin D (25(OH)D) level after 4 weeks of supplementation in postmenopausal women with vitamin D insufficiency. Study design Randomized double-blind, placebo-controlled trial. Methods Postmenopausal women who had vitamin D insufficiency were recruited into the study. The participants were randomized to 3 groups of 4-week treatment period with multivitamin (GPO, Governmental Pharmacy Organization) 2 tablets (contained vitamin D2 amount 600 units), multivitamin 1 tablet (contained vitamin D2 amount 300 units) or placebo. At baseline and after 4 weeks of supplementation, serum 25(OH)D were determined with electrochemilumines-cence immunoassay (Cobas, Roche Diagnostics) and level change of 25(OH)D level were compared among the groups. Results Out of 144 participants, 49.3% had vitamin D deficiency (<20 ng/ml) and 50.7% had vitamin D insufficiency (<30 ng/ml). However, after 4 weeks of the GPO oral multivitamin, serum 25(OH)D levels significantly increased from 19.4 ± 6.3 ng/ml at baseline to 22.2 ± 5.2 ng/ml (p = 0.01) and from 19.5 ± 5.0 ng/ml to 23.3 ± 5.2 ng/ml (p < 0.01) in the groups receiving vitamin D 300 IU and 600 IU/day, respectively. Approximately, 10% of those who took vitamin D had serum 25(OH)D level above the insufficiency level within 4 weeks. There was no significant changes of serum 25(OH)D after 4 weeks in the placebo group. Conclusions Daily supplementation of the generic multivitamin containing vitamin D2 300 and 600 IU daily for 4 weeks significantly increased mean serum 25(OH)D from baseline up above the deficiency level.

Development and validation of the Menopause-specific Quality of Life Scale for menopausal Thai women

ABSTRACT Objectives To develop a new instrument, the Menopause-specific Quality of Life Scale (MS-QoLS), for Thai women and to study the experience of menopausal aspects in peri- and postmenopausal Thai women. Materials and methods Item generation was developed from a focus group discussion and in-depth interview, and the content validity index (CVI) was computed, using item relevance ratings by content experts. Items with CVI values higher than 0.7 were selected. The draft questionnaire was tested for language, format and content. The final questionnaire was administered and the construct validity and reliability were then assessed. Results Fifty-seven peri- and postmenopausal women participated in the focus group discussion and in-depth interview. Sixty-eight items across eight dimensions were generated based on content analysis result. The dimensions included Physical health, Psychological health, Sexual health, Daily activity, Family, Social, Treatment, and Economics. A total of 280 menopausal women were recruited from four collaborative hospitals for psychometric validation. After factor analysis, 22 items remained with six dimensions identified, that is, well-being, emotionality, anxiety/fear, family, social and sexual health. Cronbachs coefficient α of each domain was between 0.61 and 0.83. Conclusion The Thai MS-QoLS was systematically developed and validated for peri- or postmenopausal women. The initial assessment of the questionnaire showed an acceptable level of validity and reliability.